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Abstract: Sonic hedgehog (Shh) signaling is critically important for embryogenesis and other cellular processes in which 
GLI transcription factors mediate the terminal effects of the pathway. GLI1, in particular, plays a significant role in hu-
man cancers. Consequently, GLI1 and its upstream positive regulator Smoothened (SMO) are important targets of anti-
cancer therapy and several SMO-targeted small molecule inhibitors are being evaluated clinically. Emerging exciting evi-
dence reveals a high level of complexity that lies within the GLI1-mediated pathway. For example, a recent study pro-
vided evidence linking the polymorphic GLI1 variants Q1100/E1100 to chronic inflammatory bowel diseases. Two recent 
reports uncovered the existence of two novel human GLI1 isoforms that differ structurally and functionally from the wild-
type GLI1 identified over two decades ago. Interestingly, although both are products of alternative splicing, GLI1N and 
tGLI1 (truncated GLI1) isoforms are predominantly expressed in normal and malignant tissues, respectively. In addition 
to these important discoveries, gene expression profiling studies have identified a number of novel wild-type GLI1 and 
tGLI1 target genes, linking wild-type GLI1 to tumor progression and therapeutic resistance, and tGLI1 to tumor invasion 
and migration. In light of these new insights, this review will provide a comprehensive overview on GLI1 polymorphisms 
and the three members of the GLI1 family of proteins, and their impacts on human diseases, including, cancers. 
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1. INTRODUCTION 
  Glioma-associated oncogene homolog 1, GLI1, was ini-
tially identified as an amplified gene in a human malignant 
glioma [1] and later, characterized to be a member of the 
Kruppel family of zinc finger-containing transcription fac-
tors [2, 3]. GLI1 and the other two members of the GLI fam-
ily, namely, GLI2 and GLI3, are the nuclear mediators of the 
Shh signaling pathway that regulates various aspects of early 
development of central nervous system [4]. For example, the 
Shh-GLI1 pathway is required for the differentiation of the 
floor cell and ventral neurons in the neural tube, granule cell 
precursor proliferation in the cerebellum, and dorsal brain 
growth [4-7]. In addition to normal development, the Shh-
GLI1 pathway is critically involved in tumorigenesis, cancer 
growth and cancer stem cell self-renewal [4, 8-10].  
  Shh-mediated signal transduction is activated following 
binding of the secreted Shh ligand
  to its receptor Patched 
(PTCH), a 12-transmembrane protein
 that inhibits the activ-
ity of the seven-transmembrane domain protein
 Smoothened 
(SMO). Shh-bound PTCH activates SMO and activated 
SMO releases GLI1 from cytoplasmic sequestration and, in 
turn, GLI1 translocates into the cell nucleus to regulate gene 
expression [9]. GLI1 binds to the consensus GLI1-binding 
element within its target genes [3], leading to activation of a 
number of genes that regulate important cellular processes,  
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such as, G1 cell cycle progression, cell proliferation and dif-
ferentiation, anti-apoptosis, tumor progression, metastasis 
and tumorigenesis.  
  Although mutations are frequently found in other com-
ponents of the Hedgehog pathway including PTCH and 
SMO, no mutations have been reported in the GLI1 gene. 
Human GLI1 gene amplification is also uncommon in most 
cancers even though it was initially identified as an ampli-
fied gene in a cancer cell line. However, the incidence rates 
for GLI1 amplification vary significantly with the highest 
frequency (28%) reported in alveolar rhabdomyosarcomas 
[11]. A number of polymorphic variants of the human GLI1 
gene have been reported, with the majority of them localized 
within the non-coding regions. For those occurring within 
the coding region of the GLI1 gene, one particular polymor-
phism at codon 1100 (Q/E) in exon 12 has attracted much 
attention because of its predictive value for chronic inflam-
matory bowel diseases [12].  
  Strikingly, more than two decades after the cloning of the 
coding region of the human GLI1 gene in 1988 [2], two al-
ternatively spliced GLI1 variants were identified by Dr. Pe-
ter Zaphiropoulos and colleagues [13] and our laboratory 
[14]. Structural and functional comparisons of the three 
GLI1 isoforms have yielded interesting results and will be 
summarized in details in later sections. In addition to ampli-
fication, polymorphism and post-transcriptional splicing, two 
GLI1 gene transcripts differing in their 5’-untranslated re-
gions due to alternative splicing of untranslated exon 1 were 
reported [15]. Interestingly, Dahlen and colleagues [16, 17] 
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22;q13-15), that result in a fusion gene product consisting 5’-
region of -actin gene and 3’-region of GLI1 gene. The zinc 
finger DNA-binding domains of GLI1 were retained in the 
fusion transcripts. Albeit the -actin-GLI1 gene fusion was 
found in soft tissue tumors, it remained unclear with regards 
to its incidences in other tissues and its physiological effects. 
Given the fact that significantly more information is avail-
able on amplification, polymorphism and post-transcriptional 
splicing of the human GLI1 gene, the review will focus on 
these aspects. 
2. GLI1 GENE AMPLIFICATION 
  GLI1 was identified as an amplified gene in a human 
glioblastoma (GBM) cell line, D-259 MG in 1987 [1]. It was 
first mapped to chromosome 12q13-14.3 by Kinzler et al. [1] 
and later, to the chromosome sub-bands 12q13.3-14.1 [18]. 
In 1998, coding region of the human GLI1 gene was deter-
mined and subsequently characterized to be a member of the 
Kruppel family of zinc finger protein [2]. Albeit the human 
GLI1 was initially isolated from a GBM cell line with GLI1 
gene amplification, the incidences of GLI1 amplification in 
human malignant gliomas were found to be relatively low as 
reported by studies conducted in the late 1980’s and early 
1990’s. It is worth noting that these earlier studies utilized a 
combination of fluorescence in situ hybridization and south-
ern blots, which is different than the more advanced genome-
wide copy-number analysis. For example, Bigner et al. [19] 
reported one out of 33 (3.3%) primary malignant gliomas to 
contain amplified GLI1 gene. Wong et al. [20] identified 
only one out of 63 (1.6%) malignant gliomas to carry GLI1 
amplification. Forus et al. [21] found 2% (2/98) of the pri-
mary GBM cohort to contain GLI1 gene amplification. In 
contrast to these observations, a more recent 2009 study [22] 
used genome-wide copy number analysis and subsequently 
identified 22.6% of 31 GBM samples to have amplified 
GLI1 gene locus.  
  GLI1 gene amplification was extensively studied in other 
types of human cancers. Several studies showed that GLI1 
amplification is absent in pediatric medulloblastoma, a 
common childhood brain cancer [23, 24]. GLI1 amplifica-
tion was reported in childhood sarcomas but the frequency 
varies considerably among different types of sarcomas. For 
example, Roberts et al. [25] found the GLI1 gene to be am-
plified in one out of 13 rhabdomyosarcomas, most common 
soft-tissue sarcoma found in children, and one out of nine 
osteosarcomas analyzed. None of the seven Ewing’s sarco-
mas contained GLI1 amplification [25]. Gordon et al. [11] 
reported 28% of 44 primary tumors and six cell lines of al-
veolar rhabdomyosarcomas to contain amplified GLI1 gene. 
Analysis of 37 primary adult sarcomas by Stein et al. re-
vealed the absence of GLI1 amplification in this tumor co-
hort [26]. Lack of GLI1 gene amplification was further re-
ported in uterine leiomyomas [27] and gastrointestinal stro-
mal tumors [28]. In bladder cancer, Simon et al. [29] found 
only 0.4% of 2,317 bladder cancer specimens to express am-
plified GLI1 gene.  
3. GENETIC POLYMORPHISM OF HUMAN GLI1 
GENE 
  Multiple single-nucleotide polymorphisms (SNPs) have 
been identified in human GLI1 gene. These SNPs are located 
in the coding region, as well as, introns and 5’- and 3’-
untranslated regions of the GLI1 gene. A full spectrum of 
these SNPs can be found at the NIH-NCBI SNPs database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). Albeit many 
SNPs are present in the human GLI1 gene, the biological 
understanding of the majority of these SNPs is very limited. 
The most extensively studied GLI1 SNPs are 2876AG 
(codon 933DG; SNP number rs2228224) and 3376CG 
(codon 1100QE; SNP number rs2228226). Interestingly, 
the first human GLI1 gene sequence isolated from D-259 
MG GBM cell line [1] contained codons G933 and E1100 
(Genbank accession number NM_005269). These alleles 
were also identified later by our laboratory [14] using an-
other GBM cell line U87MG (Genbank accession number 
GQ890670) corroborating the observations made by Kinzler 
et al. [1]. The Q1100 allele was later isolated from a healthy 
individual [30]. The GLI1 D933 allele was reported in 
healthy individuals by Hynes et al. and Kogerman et al. [31, 
32].  
  More recent studies conducted in the 2000’s further ana-
lyzed larger cohorts of healthy controls for the polymorphic 
changes of GLI1 gene and provided important information. 
Wang et al. [33] investigated a cohort of 48 healthy Austra-
lians and found the G933 allele to be the less frequent allele 
(45%) compared to the D933 allele (55%). Interestingly, 
individuals with homozygous G933 only represented 20% of 
the population analyzed while the majority of the cohort was 
either heterozygous (50%) or homozygous for D933 (30%). 
A most recent 2009 study by Lees et al. [12] further exam-
ined a total of 1374 health Scottish individuals and found the 
frequencies of G933 and D933 alleles to be 38.3% and 
61.7%, respectively. Similar to the findings by Wang et al. 
[33], Lees and the colleagues found that homozygous G933 
was the least common (16.3%) compared to heterozygous 
(44%) or homozygous for D933 (39.7%). Furthermore, Lees 
et al. examined whether associations existed between GLI1 
codon 933 polymorphism and the risks of developing ulcera-
tive colitis (UC) and Crohn’s disease (CD). Both diseases 
belong to chronic inflammatory bowel diseases that are of 
high prevalence and associated with considerable morbidity. 
A total of 474 and 335 patients with UC ad CD, respectively, 
were included in this study. The results, however, indicated 
that GLI1 codon 933 polymorphism was not significantly 
associated with increased risks for UC or CD.  
  Interestingly, the E1100 variant of the GLI1 protein was 
found to be less active in its transactivational ability com-
pared to the Q1100 variant [12]. This observation is in line 
with the fact that Q1100/E1100 is well conserved among 
different species of mammalian GLI1 proteins and is near 
the C-terminal transactivation domain (aa 1020-1091) [34]. 
Moreover, both E and Q variants appear to demonstrate a 
similar degree of nuclear translocalization as expected, since 
the nuclear localization signal (NLS) is close to the N-
terminus of the GLI1 protein. To determine the frequencies 
of polymorphic Q1100 and E1100 variants in healthy con-
trols and patients with UC and CD, as well as, the associa-
tion between GLI1 codon 1100 polymorphism and UC/CD, 
Lees  et al. [12] analyzed three large cohorts of Scottish 
(N=2191), English (N=2337) and Swedish (N=774) popula-
tions. In the Scottish cohort, a strong correlation was found 
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UC and CD. In the English cohort, a positive association was 
observed between GLI1 E1100 variant and increased risks 
for developing UC but not CD. No correlations were identi-
fied in the Swedish population. In line with these interesting 
observations, healthy Scottish controls with homozygous 
low-activity E1100 GLI1 variant only represent 8.9% of the 
cohort whereas those with the heterozygous genotype and 
homozygous Q1100 account for 42.9% and 48.3%, respec-
tively, of the study cohort. Corroborating these observations, 
Wang  et al. [33] reported a significantly lower frequency 
(2%) for the homozygous E1100 genotype compared to het-
erozygous genotype (30%) and homozygous Q1100 (68%) 
using a cohort of 48 healthy Australian individuals.  
  Taken together, GLI1 codon 1100 polymorphism appears 
to be a predictive SNP for chronic inflammatory bowel dis-
eases in some populations, such as, those of Scotland and 
England, but not Sweden. These emerging important obser-
vations should be extended to in vitro and in vivo mechanis-
tic studies that investigate the role that the GLI1 E1100 vari-
ant plays in the development of chronic inflammatory bowel 
diseases. In light of the fact that the association between 
GLI1 E1100 variant and inflammatory bowel diseases differs 
in three different ethnic groups and varies among two differ-
ent subclasses of inflammatory bowel diseases, future studies 
are also needed to understand if other genetic factors cooper-
ate with GLI1 codon 1100 polymorphism in the risk estimate 
of these diseases. It will be also of importance to further ex-
plore the frequency of GLI1 codon 1100 polymorphism in 
other human diseases, such as cancers, given the interesting 
fact that the GLI1 E1100 variant is carried by the two GBM 
cell lines (D-259 MG and U87MG) that have been geno-
typed thus far [1, 14].  
4. POST-TRANSCRIPTIONAL SPLICE VARIANTS 
OF HUMAN GLI1 GENE 
  Somatic mutations are absent in the human GLI1 gene, 
unlike other components of the Hedgehog pathway, such as, 
PTCH1 [35-39] and SMO [40-43]. Other members of the 
GLI family of transcription factors, namely, GLI2 [44] and 
GLI3 [45-47] have also been shown to undergo somatic mu-
tations and the mutants are associated with cancer risks and 
other disorders. Albeit the human GLI2 gene results in sev-
eral alternatively spliced variants with differential transcrip-
tional activity [48, 49], only one GLI1 gene transcript has 
been reported since two decades ago until very recently. In 
2008 and 2009, two alternatively spliced human GLI1 vari-
ants were identified, namely, GLI1N (Genbank accession 
number AB239136) by Shimokawa et al. [13] and tGLI1 
(truncated GLI1; Genbank accession number QB890670) by 
our laboratory [14]. These two splice variants differ from the 
wild-type full-length GLI1 both structurally and function-
ally. It is worthwhile to mention that Kinzler and colleagues 
[2] has noted in their 1988 breakthrough study that a smaller 
GLI1 transcript existed in one of the cell lines analyzed. It is 
likely that the shorter GLI1 transcript observed by these in-
vestigators corresponded to GLI1N or tGLI1, given their 
further genomic analysis of the GLI1 gene in this cell line 
indicated no structural rearrangements. 
  As shown in Fig. (1), the human GLI1 gene is consisted 
of 12 exons including 5’-untranslated exon 1. Translation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Structures of the three members of the human GLI1 family of proteins. 
The human GLI1 gene is consisted of 12 exons including 5’-untranslated exon 1. Exons are indicated as gray boxes while introns are shown 
by lines. Translation starts at ATG at nt +79 within exon 2 and is marked by arrows. The entire wild-type GLI1 coding region spans nt +79 to 
+3399 that encodes 1107 amino acids. The human GLI1N variant is a product of alternative splicing that lacks entire exons 2 and 3, in 
which the translation starts at position 129. Thus, encoded GLI1N protein contains a deletion of N-terminal 128 amino acids spanning aa 1-
128, lacking the N-terminal Dn signal and SUFU-binding domains (SU), but retains zinc-finger domains (ZF), NLS, C-terminal Dc signal, 
C-terminal SUFU-binding domain and transactivation domain. The tGLI1 transcript is also a product of alternative splicing that lacks entire 
exon 3 and partial exon 4, resulting in a deletion of 41 codons corresponding to aa 34-74. tGLI1 retains intact degron degradation signals (Dn 
and Dc; soild bars), SUFU-binding domain (clear bars), Zinc finger domains (back-slash bar), NLS (gray bar), and transactivation domain 
(dotted bar).  The Human Glioma-Associated Oncogene Homolog 1  Current Genomics, 2010, Vol. 11, No. 4    241 
starts at ATG at nt +79 within exon 2 and is marked by ar-
rows. The entire wild-type GLI1 coding region spans nt +79 
to +3399 that encodes 1107 amino acids. A number of func-
tional domains are located within the wild-type GLI1 gene 
product. Two degron degradation signals are located at the 
N- and C-termini of the GLI1 protein, namely, Dn and Dc at 
aa 77-116 and 464-469, respectively [50]. Two SUFU-
binding domains (SU) have been mapped to aa 111-125 and 
the C-terminus of the GLI1 protein [51]. SUFU-bound GLI1 
is retained in the cytoplasm [32]. There are five zinc-finger 
DNA-binding domains (ZF; aa 235-387) that enable GLI1 to 
bind to DNA sequence to activate gene expression [2]. Two 
nuclear localization signals (NLSs) consisted of basically 
charged residues are present with aa 380-420 and allow for 
nuclear import of the GLI1 protein. Located at the C-
terminus (aa 1020-1091), the transactivation domain is re-
quired for the transactivation function of GLI1 [34]. 
4.1. GLI1N Isoform 
  The human GLI1N variant is a product of alternative 
splicing that lacks entire exons 2 and 3, in which the transla-
tion starts at aa position 129 [13]. As summarized in Fig. (1), 
the encoded GLI1N protein contains a deletion of N-
terminal 128 amino acids spanning aa 1-128. Notably, 
GLI1N lacks the N-terminal Dn signal and SUFU-binding 
domains, but retains zinc-finger domains, NLS, C-terminal 
Dc signal and SUFU-binding domain, and transactivation 
domain. This alternative splicing event does not occur to the 
mouse gli1. Analysis of the GLI1N and wild-type GLI1 
transcripts in adult human normal tissues revealed their ex-
pression levels to be comparable. GLI1N expression is un-
detectable in normal brain [13, 14] and glioblastoma cells 
[14]. In several tumor cell lines, GLI1N expression was 
generally lower than wild-type GLI1. Expression of GLI1N 
and wild-type GLI1 is equally activated by the SMO agonist. 
Importantly, GLI1N demonstrated a weaker capacity than 
wild-type GLI1 to activate promoters that are under the con-
trol of consensus GLI1-binding sites and promoters of 
known GLI1 target genes, such as, PTCH and IL1R2 [13].  
  Consistent with the weaker transcriptional activity, 
GLI1N appears to undergo a lower degree of nuclear trans-
port than wild-type GLI1. However, given the fact that 
GLI1N lacks the N-terminal SUFU-binding domain, re-
duced nuclear transport is somewhat unexpected. Consistent 
with the loss of one of the two SUFU-binding domains, 
GLI1N nuclear translocalization was impacted to a lesser 
extent by forced expression of SUFU compared to wild-type 
GLI1. In summary, the discovery of GLI1N by Shimokawa 
and colleagues [13] opened a new avenue of GLI1 research 
and warrants future investigations into the role of GLI1N in 
normal development and human diseases. In light of the 
findings that GLI1N is expressed to the extent comparable 
to wild-type GLI1 in adult normal tissues and that GLI1N 
displays a weaker transcriptional activity, it will be of inter-
est to examine its expression in tissues undergoing develop-
ment and to investigate its physiological effects on embry-
onic development.  
4.2. tGLI1 Isoform 
  In an attempt to isolate and clone the human GLI1 
cDNA, we unexpectedly found that the human GBM cells 
express a truncated GLI1 (tGLI1) transcript in addition to the 
well-characterized wild-type counterpart [14]. Nucleotide 
analysis of tGLI1 indicates that it contains an in-frame dele-
tion of 123 bases, nt 179-301, that spans entire exon 3 and 
partial exon 4, and encodes 41 amino acids corresponding to 
aa 34-74 (Fig. (1)). The tGLI1 isoform retains various func-
tional domains of the wild-type GLI1, unlike GLI1N that 
loses N-terminal degron degradation signal and N-terminal 
SUFU-binding domain. To investigate whether the deletion 
is a product of genetic alternations, genomic DNAs from 
glioma cell lines, normal human astrocytes and normal adult 
peripheral blood leukocytes were extracted, PCR-amplified 
exons 2-4 and nucleotide sequences of the amplified region 
determined. The results showed no deletion at the genomic 
level, thus indicating that the tGLI1 variant is a product of 
post-transcriptional alternative splicing.  
  The majority of GBM cell lines, xenografts and primary 
specimens expressed comparable levels of tGLI1 and GLI1. 
In addition to the GBMs, tGLI1 was highly expressed in 
human breast cancer cells [14] and medulloblastoma cells 
(unpublished data). In a sharp contrast to GLI1, tGLI1 is 
undetectable in normal brain tissues and other normal tis-
sues. Consistent with the fact that tGLI1 protein retains func-
tional domains of GLI1, tGLI1 and GLI1 demonstrate simi-
lar abilities to transactivate consensus GLI1-binding sites 
and undergo nuclear translocalization. Importantly, gene 
expression profiling via DNA microarray showed that tGLI1 
not only activates GLI1 target genes but also modulates ad-
ditional set of genes. Specifically, tGLI1 activates PTCH 
expression to a similar extent compared to GLI1. In tGLI1-
expressing GBM cells, the expression of 75 genes were ex-
pressed at a significantly higher level and 26 genes more 
suppressed compared to isogenic counterparts with wild-type 
GLI1. Based on the results of gene expression profiling, 
tGLI1 may behave as a gain-of-function GLI1 transcription 
factor.  
  Importantly, tGLI1 but not GLI1 promotes migration and 
invasion of GBM cells and xenografts. One of the tGLI1 
target gene, CD24, was over-expressed in tGLI1- but not 
GLI1-expressing GBM cells and xenografts. Importantly, 
expression of CD24 is required for tGLI1-mediated increase 
of GBM migration and invasion as indicated by transcrip-
tional over-expression and down-regulation studies. The 
observed critical role that CD24 plays in the migratory and 
invasive phenotype of GBMs is consistent with its known 
role in metastasis of breast cancer and other cancers of 
epithelial origin [52, 53]. Results of protein-DNA binding 
experiments and promoter analysis further defined CD24 as 
a direct transcriptional target of tGLI1 but not GLI1 [14]. 
Deletional studies subsequently determined that a tGLI1-
binding element is located within a 0.15-kb region of the 
human CD 24 promoter.  
  The gain of function of tGLI1 in regulating CD24 tran-
scriptional activity and promoting GBM cell migration and 
invasion, its GBM-specific expression pattern, and the fact 
that it retains all the functional domains of GLI1, collec-
tively, suggest that tGLI1 may be a more important mediator 
of GBM cellular physiology and behavior than GLI1. These 
results are significant given the fact that GBM is the most 
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infiltrative and resistant to therapy [54-57]. These findings 
provide a rationale for investigations for the presence of and 
function of tGLI1 in other tumors known to have active 
Hedgehog signaling and to be highly metastatic. The discov-
ery of tGLI1 is, thus, highly significant and is likely to open 
up novel concepts of the role of GLI1 in tumor biology and 
may provide the basis for novel treatment strategies. Yet 
answered by this initial discovery, however, are the mecha-
nisms underlying tGLI1-mediated transcriptional regulation 
and the impact of tGLI1 on other malignant biology of hu-
man cancers and on oncogenesis.  
  In summary, recent discoveries of novel human GLI1 
isoforms have shed new light on the hedgehog signaling 
pathway. Given the differential functions displayed by the 
three GLI1 proteins, alternatively splicing may play a sig-
nificant role in the functional regulation of GLI1. This is 
particularly important since genetic alterations GLI1 are very 
rare. It is thus important to extend our research efforts to 
finding physiological and pathological effects of the two 
newly identified GLI1 isoforms. Also unanswered by these 
discoveries, are the mechanisms that regulate the alternative 
splicing events. In this regard, gaining an understanding of 
the regulatory factors that switch on tGLI1 expression in 
cancerous cells may lead to a means of silencing tGLI1 ex-
pression and thereby inhibits tumor invasiveness and migra-
tion.  
5. TRANSCRIPTIONAL TARGETS OF THE GLI1 
FAMILY OF TRANSCRIPTION FACTORS 
  GLI1 protein binds to a 9-base-pair DNA element 5’-
GACCACCCA-3’ within its target genes to regulate gene 
expression [3]. Through gene regulation, the GLI1 family of 
proteins regulates a number of important cellular processes, 
such as, neural development, cell proliferation, oncogenesis, 
survival, epithelial-mesenchymal transition (EMT), migra-
tion, invasion and metastasis [58] (Fig. (2)). As positive and 
negative feedbacks,  GLI1 protein respectively activates its 
own expression and that of PTCH1 [59]. Specifically, GLI1 
binds to an inverted GLI1-binding site, 5’-TGGGTGGTC-3’ 
in the PTCH1 promoter leading to gene activation. The 
tGLI1 protein activates PTCH1 expression to a similar de-
gree as the wild-type GLI1 [14].  
  The first identified GLI1 target gene was hepatocyte nu-
clear factor-3, HNF-3 [60]. HNF-3 is  a  winged helix 
transcription factor that plays a critical role in the develop-
ment of floor plate which is essential for ventral pattern for-
mation and axonal guidance within the neural tube of verte-
brate embryos. GLI1 directly binds to a GLI1-binding site 
(5’-GAACACCCA-3’) within the HNF-3 promoter to acti-
vate HNF-3 gene expression, linking the Hedgehog path-
way to neuronal development [60]. In addition to HNF-3, 
GLI1 regulates expression of other transcription factors, in-
cluding, FOXM1 [61] and Jun [62]. FOXM1 belongs to the 
Forkhead box (FOX) family of proteins that regulates genes 
involved in cell proliferation, differentiation, aging, and 
transformation. Teh et al. [61] showed that forced expression 
of GLI1 in primary keratinocytes and other cell lines caused 
a significant elevation of FOXM1 transcripts and promoter 
activity, albeit it is unknown whether a GLI1-binding site is 
located in the FOXM1 promoter. Most recently, Laner-
Plamberger et al. [62] reported that GLI1 directly binds to a 
GLI1-binding site (5’-GGCCCCCCA-3’) within the human 
Jun promoter, leading to its transcriptional activation in the 
skin.  
  GLI1 mediates cell proliferation via activating expression 
of several positive regulators of cell-cycle progression, such 
as, inhibitors of Rb tumor suppressor, cyclins. For example, 
GLI1 activates expression of the human cyclin D2 gene fol-
lowing binding to a GLI1-binding site, 5’-CACCACCCA-3’, 
in the cyclin D2 gene promoter [63]. The Drosophila ho-
molog of GLI1, Ci, directly associates with promoters of 
cyclin D and cyclin E to upregulate their transcription [64]. 
In contrast, GLI1 has been shown to also activate insulin-like 
growth factor binding protein-6 (IGFBP-6) [63] that is anti-
proliferative. IGFBP-6 differs from other IGFBPs for its 
IGF-II binding specificity and subsequent inhibition of IGF-
II actions [65]. IGFBP-6 appears to inhibit growth of IGF-II-
dependent cancers, including rhabdomyosarcoma, neuroblas-
toma and colon cancer.  
  Accumulating evidence suggests an essential role that 
GLI1 plays in tumor progression and metastasis. GLI1 in-
duces expression of E-cadherin repressor, Snail, although the 
exact binding site remains to be identified [66, 67]. Snail, 
Slug and TWIST belong to a host of EMT regulators that 
primarily function as transcriptional repressors of cell-cell 
junction protein, E-cadherin [68]. Loss of cell-cell junction is 
an essential step of EMT. Furthermore, GLI1 appears to 
upregulate a chemokine receptor CXCR4 that plays an im-
portant role in metastasis [69]. Plus, GLI1 up-regulates ex-
pression of rat, mouse and human osteopontin genes [63, 
70]. Specifically, GLI1 binds to the GLI1-binding site (5-
 
 
 
 
 
 
 
 
Fig. (2). The GLI1 family of transcription factors regulates expression of a host of target genes that thereby mediates a number of important 
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TGCTGAATGCCCATCCC-3’) within the human osteopon-
tin gene [70]. Osteopontin is a glycoprotein expressed by 
various tissues and cells as secreted and intracellular proteins 
[71]. Secreted osteopontin interacts with integrins and CD44 
to mediate cell adhesion, migration and tumor invasion. 
Overexpression of osteopontin is associated with invasion 
and metastasis of melanoma and squamous cell carcinoma 
cells. In line with this notion, Das et al. [70] found that 
GLI1-mediated upregulation of osteopontin leads to in-
creased migration, invasion and proliferation of melanoma 
cells and increased metastasis of melanoma xenografts in 
nude mice. Conversely, transcriptional knockdown of GLI1 
reduces osteopontin expression, leading to reduced metasta-
sis. Our laboratory showed that tGLI1 protein promotes cell 
migration and invasion by binding to a 0.15-kb region (nt -
294 to -141) of the CD24 promoter and activating CD24 
expression. CD24 has been shown to recruit adhesion mole-
cules to lipid rafts, thereby, contributing to tumor cell migra-
tion, dissemination and metastasis [52, 53]. Together, the 
emerging evidence indicates that the GLI1 family of proteins 
may play an important role in tumor progression and metas-
tasis.  
  Additional evidence suggests a potential involvement of 
GLI1 in therapeutic response of human cancers. For exam-
ple, GLI1 activates expression of anti-apoptotic protein bcl-2 
in keratinocytes [72]. A functional GLI1-binding site, 5’-
GACCACCAA-3’, is located in the bcl-2 gene promoter. 
The functional consequences of GLI1-mediated bcl-2 up-
regulation, such as, cell survival, remain to be elucidated. In 
medulloblastomas, GLI1 has been linked to increased ex-
pression of tumor suppressor p53 and O-6-methylguanine-
DNA methyltransferase, MGMT [69]. While GLI1 may indi-
rectly activate p53, it may directly activate the MGMT gene 
given that the MGMT gene promoter contains a putative 
GLI1-binding site. Although the study by Yoon et al. did not 
provide direct evidence linking GLI1 to therapeutic resis-
tance, both p53 and MGMT have known involvement in 
drug resistance. In gliomas, the presence of p53 results in 
higher resistance to cisplatin than when the gene is mutated 
and/or functionally inactive [73]. Abrogation of the wild-
type p53, e.g. via antisense oligonucleotides, sensitizes tu-
mor cells to cisplatin. This is consistent with the fact that p53 
activates expression of cisplatin-metabolizing enzyme, 
GSTP1 [74]. Similar observations of wild-type p53 confer-
ring drug resistance or decreased drug sensitivity have also 
been made in other cancer types, such as, breast, bladder, 
and ovarian carcinomas [75-77]. MGMT is known to repair 
O-6-alkylguanine DNA lesions caused by an anti-cancer 
alkylator, temozolomide [78]. The impact of GLI1-mediated 
upregulation of p53 and MGMT on therapeutic response in 
human cancers remains to be investigated.  
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GLI1  =  Glioma-associated oncogene homologue 1 
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MGMT   =  O-6-methylguanine DNA methyltransferase 
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SUFU =  Suppressor-of-Fused   
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